The hospitalization burden of inflammatory bowel disease in China: a nationwide study from 2013 to 2018

BACKGROUND: The past decade has witnessed a dramatic increase in the number of patients with inflammatory bowel disease (IBD) in China. The nationwide burden of hospitalization remains unclear, however. We aimed to address this gap by conducting analysis using a nationwide database. METHODS: Population-based hospitalization rates from 2013 to 2018 were calculated by extrapolating the number of patients in the database to the national level. Surgical rates, annual hospital charges, and length of stay were also used for quantification of hospitalization burden. The Poisson regression analysis and the Cochran–Armitage trend test were conducted to analyze temporal trends as expressed as annual percentage of change (APC) with 95% confidential intervals (CIs). RESULTS: From 2013 to 2018, the hospitalization rates for Crohn’s disease (CD) and ulcerative colitis (UC) in China increased from 2.20 (95% CI = 2.17–2.22) to 3.62 (3.59–3.65) per 100,000 inhabitants (p < 0.0001) with an APC of 10.68% (6.00–15.36%) and from 6.24 (6.20–6.28) to 8.29 (8.23–8.33) per 100,000 inhabitants (p < 0.0001) with an APC of 5.73% (2.32–9.15%), respectively. Surgical rates decreased from 7.96% (7.29–8.63%) to 5.56% (5.11–6.00%) for CD patients (p < 0.0001) with APC of −6.30% (−11.33 to −1.27%) and from 3.54% (3.26–3.82%) to 2.52% (2.32–2.72%) for UC patients (p < 0.0001) with APC of −6.35% (−16.21 to 3.51). In 2018, there were estimated 166,000 IBD patients hospitalized costing a total of $426.37 million ($149.91 + $276.46 million) across the entire China. CONCLUSION: The population-based hospitalization rate of IBD increased, whereas the surgical rate decreased from 2013 to 2018 in China.